Literature DB >> 1560787

Establishment of a cell line from the EHS tumor: biosynthesis of basement membrane constituents and characterization of a hybrid proteoglycan containing heparan and chondroitin sulfate chains.

K G Danielson1, A Martinez-Hernandez, J R Hassell, R V Iozzo.   

Abstract

We have established a continuous cell line from the Engelbreth-Holm-Swarm (EHS) tumor, a transplantable murine neoplasm that has been extensively utilized to investigate basement membrane constituents. The EHS-derived cells, designated BAM cells, have been subcultured for over 40 passages and have maintained phenotypic and biological properties of the parent EHS tumor cells. BAM cells have retained an epithelioid morphology and the ability to induce EHS-like tumors in mice. Biochemical and immunochemical studies demonstrated that BAM cells synthesize laminin A and B chains, collagen type IV, entactin and the basement membrane specific heparan sulfate proteoglycan. Interestingly, the proteoglycan synthesized by BAM cells was a hybrid molecule containing 2-3 heparan sulfate chains of 25-35 kDa and 1 chondroitin sulfate chain of approximately 17 kDa attached to a 400-kDa protein core. This cell line will be useful to investigations concerning biosynthesis of basement membrane constituents and will be a valuable source of extracellular matrix for testing cellular properties such as attachment, locomotion and differentiation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1560787     DOI: 10.1016/s0934-8832(11)80101-0

Source DB:  PubMed          Journal:  Matrix        ISSN: 0934-8832


  11 in total

Review 1.  Proteoglycans of basement membranes.

Authors:  R Timpl
Journal:  Experientia       Date:  1993-05-15

Review 2.  The biology of perlecan: the multifaceted heparan sulphate proteoglycan of basement membranes and pericellular matrices.

Authors:  R V Iozzo; I R Cohen; S Grässel; A D Murdoch
Journal:  Biochem J       Date:  1994-09-15       Impact factor: 3.857

3.  Tumorigenic conversion of p53-deficient colon epithelial cells by an activated Ki-ras gene.

Authors:  C Sevignani; P Wlodarski; J Kirillova; W E Mercer; K G Danielson; R V Iozzo; B Calabretta
Journal:  J Clin Invest       Date:  1998-04-15       Impact factor: 14.808

Review 4.  Heparan sulfate proteoglycans.

Authors:  Stephane Sarrazin; William C Lamanna; Jeffrey D Esko
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-07-01       Impact factor: 10.005

5.  Altered Proteoglycan Gene Expression in Human Biliary Cirrhosis.

Authors:  Julia O Nagy; Mónika Gallai; Anna Sebestyén; Zsuzsa Schaff; Sándor Paku; András Jeney; Renato V Iozzo
Journal:  Pathol Oncol Res       Date:  1997       Impact factor: 3.201

6.  cDNA cloning of the basement membrane chondroitin sulfate proteoglycan core protein, bamacan: a five domain structure including coiled-coil motifs.

Authors:  R R Wu; J R Couchman
Journal:  J Cell Biol       Date:  1997-01-27       Impact factor: 10.539

7.  The proteoglycan perlecan is expressed in the erythroleukemia cell line K562 and is upregulated by sodium butyrate and phorbol ester.

Authors:  S Grässel; I R Cohen; A D Murdoch; I Eichstetter; R V Iozzo
Journal:  Mol Cell Biochem       Date:  1995-04-12       Impact factor: 3.396

8.  Proteoglycan production by human glomerular visceral epithelial cells and mesangial cells in vitro.

Authors:  N F van Det; J van den Born; J T Tamsma; N A Verhagen; L P van den Heuvel; J H Berden; J A Bruijn; M R Daha; F J van der Woude
Journal:  Biochem J       Date:  1995-05-01       Impact factor: 3.857

9.  An in vivo function for the transforming Myc protein: elicitation of the angiogenic phenotype.

Authors:  C V Ngo; M Gee; N Akhtar; D Yu; O Volpert; R Auerbach; A Thomas-Tikhonenko
Journal:  Cell Growth Differ       Date:  2000-04

10.  Similarity of recombinant human perlecan domain 1 by alternative expression systems bioactive heterogenous recombinant human perlecan D1.

Authors:  April L Ellis; Wensheng Pan; Guang Yang; Kim Jones; Christine Chuang; John M Whitelock; Arthur A DeCarlo
Journal:  BMC Biotechnol       Date:  2010-09-09       Impact factor: 2.563

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.